(Bloomberg) -- Deutsche Bank AG’s top accounting executive, Andreas Loetscher, and two ex-colleagues at his former firm Ernst & Young were targeted in a criminal complaint by a German retail investor association for their alleged role in the accounting scandal at Wirecard AG.The SdK association filed the claim against two unnnamed current partners of EY -- which also audits Deutsche Bank’s accounts -- and one former partner because of “the events around Wirecard,” according to a statement on Friday. That ex-partner is Loetscher, a person familiar with the matter said.Loetscher, a two-decade veteran at the accounting firm, oversaw the Wirecard audits for the financial years 2015 through 2017, filings show. He left in 2018 to become chief accounting officer at Deutsche Bank, taking over after the bank struggled for years with legal and regulatory mishaps.”There are many unresolved questions around Wirecard,” Deutsche Bank said in a statement. “We highly appreciate working...
This year has been somewhat quiet for Alibaba (NYSE:BABA). Alibaba stock has gained a little less than 5%. That's a solid performance, given some broad indices remain negative year to date. But it's surely not what bulls hoped for at the beginning of the year.Source: Kevin Chen Photography / Shutterstock.com Alibaba has seen some volatility along the way. From January highs to March lows, the stock dropped a little over 25%. But many quality names saw much bigger moves. Relative to the market as a whole, Alibaba's stock just hasn't stood out.At this point, perhaps that's not all that surprising. Alibaba is the sixth-most valuable company listed on U.S. exchanges. Its market capitalization is larger than those of giants like Visa (NYSE:V) and Johnson & Johnson (NYSE:JNJ). The company accounts for a staggering percentage of the Chinese economy: over 5%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBased on size...
If you've followed any technology trends over the last 10 years, you know very well that electric vehicles are all the rage. Thus, it's no surprise that the space has expanded to include two-wheeled variants. And that's great news for Niu Technologies (NASDAQ:NIU), which specializes in electric-powered scooters. Perhaps the only problem for Niu Technologies stock is that shares have skyrocketed this year, potentially dissuading prospective buyers.Source: TY Lim / Shutterstock.com But if you're in that boat, you may want to reconsider your mindset. Just one year ago, people would have thought you were nuts if you had suggested that shares of Tesla (NASDAQ:TSLA) would challenge four-digit prices 365 days later. Yet here we are.Of course, it's not just investor sentiment that has sparked this paradigm shift. Instead, it's the underlying technology. What Tesla did was prove that a new platform could challenge the combustion-engine hegemony. When it did that, it...
Once again, value stocks are underperforming. For most of the bull market that ended in March, growth names were in favor. In the recovery from mid-March lows, once again high-valuation, high-growth stocks have led the way.At some point, presumably, that will change. Growth names no doubt have benefited from lower interest rates, which have brought capital into the equity markets and, at least in theory, increase the value of out-year profits. But there is a point where valuations, even for the market's biggest winners, will have to matter. With the NASDAQ Composite now positive year-to-date despite a global pandemic, that point may be arriving soon.In the meantime, some caution is advised. Cheap stocks in recent years generally have stayed cheap. But, as always, the wheel will turn, and when it does there are value stocks with solid upside potential.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Consumer...
Yahoo Finance’s Alexis Christoforous and Brian Sozzi discuss the rising number of coronavirus cases in the U.S. and what the government's options are with Raymond James Healthcare Policy Analyst, Chris Meekins....
AstraZeneca's experimental COVID-19 vaccine is probably the world's leading candidate and most advanced in terms of development, the World Health Organization's (WHO) chief scientist said on Friday. The British drugmaker has already begun large-scale, mid-stage human trials of the vaccine, which was developed by researchers at University of Oxford. This week, AstraZeneca signed its tenth supply-and-manufacturing deal....
